drugset

drugset / Trial / NCT00561964

Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria

NCT00561964 ↗

Phase 3 Completed 241 enrolled Sanofi Bristol-Myers Squibb · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effects and safety of irbesartan on proteinuria in hypertensive patients with type Ⅱdiabetes mellitus.

Timeline

Start: 2004-01
Primary completion: —
Completion: 2005-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irbesartan	Small molecule	300 mg	—

Indications